On the Treatment of COVID-19

COVID19 - CORONAVIRUS, 6 Jul 2020

Swiss Policy Research - TRANSCEND Media Service

3 Jul 2020 – Immunological and serological studies show that a large part of the population develops no symptoms or only mild symptoms due to the new coronavirus, while some people may experience a more pronounced or critical course of the disease.

Based on the available scientific evidence and current clinical experience, the SPR Collaboration recommends that physicians and authorities consider the following treatment protocol for early treatment of the Covid-19 disease (see below for references).

Note: Patients are asked to consult a doctor.

Treatment protocol

1. Zinc (approx. 100mg per day)
2. Vitamins C and D3 plus quercetin
3. Hydroxychloroquine (approx. 400mg per day)
4. Azithromycin (approx. 500mg per day)
5. Heparin (usual dosage)

Explanatory notes

1. Zinc: Antiviral properties (see references below). Zinc may be used prophylactically or immediately when the first mild symptoms appear. For some patients, treatment with high-dose zinc (100mg per day) may already be sufficient to prevent progression of the disease.
2. Vitamins C and D3: Support of the immune system (also prophylactically). These may be supplemented by the antiviral flavonoid quercetin, which supports the absorption of zinc.
3. Hydroxychloroquine (HCQ): Support of the cellular uptake of zinc as well as additional antiviral properties. If prescribed by a doctor, HCQ may be used immediately upon the onset of the first mild symptoms or even prophylactically. Contraindications (e.g. favism) must be observed.
4. Azithromycin: Antibiotic to prevent a bacterial superinfection in case of viral pneumonia. In patients at risk and as prescribed by a doctor, azithromycin may be used immediately after the first mild symptoms appear. Contraindications must be observed.
5. Heparin: Anticoagulation (blood clotting inhibition) for prophylaxis or treatment of infection-related thrombosis and pulmonary embolism in patients at risk and as prescribed by a doctor.

In all cases, early treatment as soon as the first mild symptoms appear and even without a PCR test is crucial to prevent progression of the disease. Zinc and HCQ may also be used prophylactically.

The alleged or actual negative results with HCQ in some studies were based, according to the current state of knowledge, on delayed use (intensive care patients), excessive doses (up to 2400mg per day), manipulated data sets, or ignored contraindications (e.g., favism).

Early treatment based on the above protocol is intended to avoid hospitalization. If hospitalization nevertheless is required, experienced ICU doctors recommend avoiding invasive ventilation (intubation) whenever possible and using oxygen therapy (HFNC) instead.

It is conceivable that the above treatment protocol, which is simple, safe and inexpensive, could render more complex medications, vaccinations, and other measures largely obsolete. US doctors have already reported very significant treatment successes with zinc HCQ protocols.

References

General

• EVMS Critical Care Covid-19 Management Protocol (Paul Marik, MD, June 2020)

Zinc

• Study: Effect of Zinc Salts on Respiratory Syncytial Virus Replication (Suara & Crowe, AAC, 2004)
• Study: Zinc Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture (Velthuis et al, PLOS Path, 2010)
• Study: Zinc for the common cold (Cochrane Systematic Review, 2013)
• Study: Chloroquine Is a Zinc Ionophore (Xue et al, PLOS One, 2014)
• Study: Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients (Carlucci et al., MedRxiv, May 2020)
• Review: Does zinc supplementation enhance the clinical efficacy of chloroquine/ hydroxychloroquine to win today’s battle against COVID-19? (Derwand & Scholz, MH, 2020)
• Review: Zinc supplementation to improve treatment outcomes among children diagnosed with respiratory infections (WHO, Technical Report, 2011)
• Article: Can Zinc Lozenges Help with Coronavirus Infections? (McGill, March 2020)

Hydroxychloroquine

• Studies: Overview of more than 60 international HCQ studies (C19Study.com)
• Study: Chloroquine is a potent inhibitor of SARS coronavirus infection and spread (Vincent et al., Virology Journal, 2005)
• Study: Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world (Million et al., New Microbes and New Infections, June 2020)
• Article: Using Hydroxychloroquine and Other Drugs to Fight Pandemic (Yale School of Medicine)
• Article: Moroccan Scientist: Morocco’s Chloroquine Success Reveals European Failures (Morocco World News, 22 June 2020) Zemmouri believes 78% of Europe’s coronavirus-related deaths could have been avoided if European states had mirrored Morocco’s chloroquine strategy.
• Article (IT): Covid, none of my patients are dead, and only 5% had to be hospitalized (Italia Oggi, June 2020) Dr. Cavanna treated the affected by the virus by intervening promptly and at home.

Quercetin

• Study: Zinc Ionophore Activity of Quercetin and Epigallocatechin-gallate: From Hepa 1-6 Cells to a Liposome Model (Dabbagh et al., JAFC, 2014)
• Study: Quercetin as an Antiviral Agent Inhibits Influenza A Virus Entry (Wu et al, Viruses, 2016)
• Study: Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (Biancatelli et al, Front. in Immun., June 2020)
• Report: EVMS Critical Care Covid-19 Management Protocol (Paul Marik, MD, June 2020)

Heparin

• Commentary: The versatile heparin in COVID‐19 (Thachil, JTH, April 2020)
• Study: Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy (Tang et al, JTH, May 2020)
• Study: Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 (Wichmann et al., Annals of Internal Medicine, May 2020)
• Article: Anticoagulation Guidance Emerging for Severe COVID-19 (Medpage Today)

See also:

• Facts about Covid-19
• Studies on the lethality of Covid-19

__________________________________________

Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.

Languages: DE, EN

Go to Original – swprs.org

Share this article: email mastodon facebook 🔗 copy link

DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Comments are closed.